Investigating how genetic factors affect immune responses in lung cancer treatment
Human leukocyte antigen and immune response in non-small cell lung cancer: A multi-omics approach
This study is looking at how certain genes in your immune system might affect how well you respond to cancer treatments if you have non-small cell lung cancer, with the goal of finding ways to personalize your treatment for better results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11035860 on NIH RePORTER |
What this research studies
This research focuses on understanding how variations in human leukocyte antigen (HLA) genes influence the immune response to cancer therapies in patients with non-small cell lung cancer (NSCLC). By analyzing a large dataset that includes genetic, tumor, and clinical information, the study aims to identify new biomarkers that can predict which patients are likely to benefit from immune checkpoint inhibitors. The approach combines advanced statistical techniques and machine learning to uncover the complex interactions between genetics and immune response. Patients may have their genetic information analyzed to help tailor more effective treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing treatment with immune checkpoint inhibitors.
Not a fit: Patients with other types of lung cancer or those who are not eligible for immune checkpoint inhibitor therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in using genetic markers to predict responses to cancer therapies, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Harvard School of Public Health — Boston, United States (Active)
Researchers
- Principal investigator: Wang, Xinan — Harvard School of Public Health
- Study coordinator: Wang, Xinan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.